抗体医药品：各种技术和全球市场

全球抗体医药品市场规模预计将从 2024 年的 年终的 4,121 亿美元，预测期内复合年增长率为 11.2%。

北美地区预计将从 2024 年的 1,322 亿美元成长到 2029年终的2,159 亿美元，复合年增长率为 10.3%。此外，欧洲地区预计将从2024年的716亿美元成长到2029年终的1,269亿美元，复合年增长率为12.1%。

本报告调查了全球抗体医药品市场，并提供了市场概况、市场影响因素和市场机会、法律制度、新兴技术和技术发展趋势、市场规模趋势和预测以及各个细分市场和地区的分析。了详细分析、竞争格局、主要企业概况等。

目录

第一章执行摘要

• 市场展望
• 调查范围
• 市场分析

第二章 市场概况

• 抗体和抗原
• 抗体功能
• 单株抗体
• 单株抗体的历史
• 单株抗体：优点和缺点
• 单株抗体的类型
• 单株抗体製造技术
• 单株抗体的用途

第三章市场动态

• 促进因素
• 癌症和自体免疫疾病的发生率增加
• 新产品发布
• 抑制因素
• 高价格和价格压力
• 单株抗体的副作用和局限性
• 机会
• 授权和合作协议
• 製造进步和产品产量比率提高

第四章 监管方面

• 监管场景
• 价格管制
• 单株抗体新核准

第五章新兴技术与发展

• 概述
• 新兴技术
• 双特异性和多特异性抗体
• 抗体药物复合体
• 抗体融合蛋白
• 抗体医药品工程中的人工智慧和机器学习

第六章市场区隔分析

• 细分细分
• 全球抗体医药品市场：按抗体类型
• 人类单株抗体
• 人源化单株抗体
• 嵌合体单株抗体
• 鼠源性单株抗体
• 全球抗体医药品市场：依製造流程划分
• 哺乳动物细胞培养
• 微生物细胞发酵
• 全球抗体医药品市场：依应用分类
• 自体免疫疾病
• 固态肿瘤
• 淋巴瘤、白血病、多发性骨髓瘤
• 其他的
• 地域分布
• 全球抗体医药品市场：按地区
• 市场规模/预测
• 北美洲
• 欧洲
• 亚太地区
• 其他领域

第七章 竞争讯息

• 竞争格局
• 人类单株抗体市场占有率
• 人源化单株抗体市场占有率
• 嵌合体单株抗体市场占有率

第八章 新进展和临床试验活动

• 新进展及併购分析
• 临床试验活动
• I期临床试验
• II期临床试验
• III期临床试验
• IV期临床试验

第 9 章永续性：抗体医药品市场的 ESG 视角

• 抗体医药品市场的永续性
• 了解 ESG资料
• 环境绩效
• 社会表现
• 管治绩效
• BCC的结语

第10章附录

• 调查方法
• 来源
• 缩写词
• 公司简介
• ABBVIE INC.
• AMGEN INC.
• ASTRAZENECA
• BRISTOL-MYERS SQUIBB CO.
• F. HOFFMANN-LA ROCHE LTD.
• JOHNSON & JOHNSON SERVICES INC.
• LILLY
• MERCK KGAA
• NOVARTIS AG
• PFIZER INC.
• REGENERON PHARMACEUTICALS INC.
• SANOFI

The global market for antibody drugs is expected to grow from $242.6 billion in 2024 and is projected to reach $412.1 billion by the end of 2029, at a compound annual growth rate (CAGR) of 11.2% during the forecast period of 2024 to 2029.

The North American market for antibody drugs is expected to grow from $132.2 billion in 2024 and is projected to reach $215.9 billion by the end of 2029, at a CAGR of 10.3% during the forecast period of 2024 to 2029.

The European market for antibody drugs is expected to grow from $71.6 billion in 2024 and is projected to reach $126.9 billion by the end of 2029, at a CAGR of 12.1% during the forecast period of 2024 to 2029.

Report Scope

This study offers a global view of the antibody drugs that have become key components of the pharmaceutical and biopharmaceutical markets. It analyzes and assesses therapeutic applications of monoclonal antibodies (mAbs) in human medicine, including the combination of mAbs when attached to cytotoxic agents such as antibody drug conjugates (ADCs).

BCC Research analyzed and made projections of each market and its applications, along with an analysis of the regulatory environment, new products and technological advances. Also included in the report are profiles of leading companies in the antibody drug industry, such as AbbVie Inc., Amgen Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., and Merck KGaA.

Monoclonal antibodies are finding growing use in the treatment of chronic diseases. This report focuses on the global market for antibody drug products and provides an updated review of their applications in various disease sectors. The overall market for antibody drug products includes four primary areas of applications: autoimmune diseases; solid tumors; lymphoma and leukemia; and other diseases such as asthma, osteoporosis and cardiovascular diseases.

This report excludes polyclonal antibodies, screening kits and diagnostic uses of mAbs. It also excludes the research applications of mAbs and therapeutic antibodies for veterinary use. The report excludes antibody products for COVID-19 and vaccine-based products.

The market is segmented by geographical region: North America, Europe, Asia-Pacific, and the Rest of the World (RoW). Regional analysis is further broken down by country as follows: North America-the U.S., Canada and Mexico; Europe-Germany, the U.K., France, Italy, Spain, and the Rest of Europe; Asia-Pacific-China, Japan, India, South Korea, Australia, and the Rest of Asia-Pacific. For market estimates, data has been provided for 2021 and 2022 as the historic years, 2023 as the base year, and forecasts through 2029.

Report Includes

• 76 data tables and 55 additional tables
• An updated review of the global market for antibody drugs
• Analyses of the global market trends, with data from 2021-2023, estimates for 2024, and projections of compound annual growth rates (CAGRs) through 2029
• Evaluation of the overall market for antibody drugs, and corresponding market share analysis by type, manufacturing process, application, and region
• Description of antibody functions and how they compare with antigens, and a discussion of monoclonal antibodies (mAbs), including their history, advantages and disadvantages, types, manufacturing technologies and applications
• Coverage of new approvals, recalls, safety alerts and clinical trials of mAbs, as well as technical issues related to human anti-mouse antibody (HAMA), and factors affecting mAB drugs
• An assessment of the major technologies for the formulation of antibody drugs and their relation to biotechnology, immunology, pharmaceuticals, and biodefense companies
• Discussions of the market dynamics, opportunities and challenges, as well as emerging technologies
• Overview of the sustainability trends and ESG developments in the industry, with emphasis on the ESG practices followed by leading companies, their ESG ratings, and consumer attitudes
• Competitive intelligence, including companies' market shares, recent M&A activity and venture funding
• Profiles of the leading companies, including F. Hoffmann-La Roche Ltd., Johnson & Johnson Services Inc., AbbVie Inc., Merck KGaA, and Amgen Inc.

Table of Contents

Chapter 1 Executive Summary

• Market Outlook
• Scope of Report
• Market Insights

Chapter 2 Market Overview

• Antibodies and Antigens
• Antibody Functions
• Monoclonal Antibodies
• History of Monoclonal Antibodies
• Monoclonal Antibodies: Advantages and Disadvantages
• Types of Monoclonal Antibodies
• Manufacturing Technologies of Monoclonal Antibodies
• Applications of Monoclonal Antibodies

Chapter 3 Market Dynamics

• Drivers
• Increasing Incidence of Cancer and Autoimmune Diseases
• New Product Launches
• Restraints
• High Prices and Pricing Pressure
• Side Effects and Limitations of mAbs
• Opportunities
• Licensing and Collaboration Agreements
• Manufacturing Advances and Improving Product Yields

Chapter 4 Regulatory Aspects

• Regulatory Scenario
• Price Controls
• New Approvals of Monoclonal Antibodies

Chapter 5 Emerging Technologies and Developments

• Overview
• Emerging Technologies
• Bispecific Antibodies and Multi-Specific Antibodies
• Antibody-Drug Conjugates
• Antibody Fusion Proteins
• AI and ML in Antibody Drug Engineering

Chapter 6 Market Segmentation Analysis

• Segmentation Breakdown
• Global Market for Antibody Drugs, by Antibody Type
• Human Monoclonal Antibodies
• Humanized Monoclonal Antibodies
• Chimeric Monoclonal Antibodies
• Murine Monoclonal Antibodies
• Global Market for Antibody Drugs, by Manufacturing Process
• Mammalian Cell Culture
• Microbial Cell Fermentation
• Global Market for Antibody Drugs, by Application
• Market by Application
• Autoimmune Diseases
• Solid Tumors
• Lymphoma, Leukemia and Multiple Myeloma
• Others
• Geographic Breakdown
• Global Market for Antibody Drugs, by Region
• Market Size and Forecast
• North America
• Europe
• Asia-Pacific
• Rest of the World (RoW)

Chapter 7 Competitive Intelligence

• Competitive Landscape
• Market Share for Human Monoclonal Antibodies
• Market Share for Humanized Monoclonal Antibodies
• Market Share for Chimeric Monoclonal Antibodies

Chapter 8 New Developments and Clinical Trial Activities

• New Developments and M&A Analysis
• Clinical Trial Activities
• Phase I Clinical Trials
• Phase II Clinical Trials
• Phase III Clinical Trials
• Phase IV Clinical Trials

Chapter 9 Sustainability: An ESG Perspective in the Antibody Drugs Market

• Sustainability in the Antibody Drugs Market
• Understanding the ESG Data
• Environmental Performance
• Social Performance
• Governance Performance
• Concluding Remarks from BCC

Chapter 10 Appendix

• Methodology
• Sources
• Acronyms
• Company Profiles
• ABBVIE INC.
• AMGEN INC.
• ASTRAZENECA
• BRISTOL-MYERS SQUIBB CO.
• F. HOFFMANN-LA ROCHE LTD.
• JOHNSON & JOHNSON SERVICES INC.
• LILLY
• MERCK KGAA
• NOVARTIS AG
• PFIZER INC.
• REGENERON PHARMACEUTICALS INC.
• SANOFI

List of Tables

• Summary Table : Global Market for Antibody Drugs, by Region, Through 2029
• Table 1 : Evolution of Monoclonal Antibodies, 1908-2024
• Table 2 : Advantages and Disadvantages of Monoclonal Antibodies
• Table 3 : Differences between Hybridoma and Recombinant Technologies
• Table 4 : Incidence and Mortality Rates of Cancer Across Regions, 2022
• Table 5 : Therapeutic Area Distribution of Approved Antibody Drugs, 2023*
• Table 6 : Approved Antibody Products for Rare Autoimmune Diseases
• Table 7 : Listed Pricing of Select Antibody Drugs in the U.S.
• Table 8 : Newly Approved Monoclonal Antibodies, 2022-July 2024
• Table 9 : Top Selling Antibody Drugs, 2023
• Table 10 : Global Market for Antibody Drugs, by Antibody Type, Through 2029
• Table 11 : Global Market for Human Monoclonal Antibodies, by Region, Through 2029
• Table 12 : North American Market for Human Monoclonal Antibodies, by Country, Through 2029
• Table 13 : European Market for Human Monoclonal Antibodies, by Country, Through 2029
• Table 14 : Asia-Pacific Market for Human Monoclonal Antibodies, by Country, Through 2029
• Table 15 : Global Market for Humanized Monoclonal Antibodies, by Region, Through 2029
• Table 16 : North American Market for Humanized Monoclonal Antibodies, by Country, Through 2029
• Table 17 : European Market for Humanized Monoclonal Antibodies, by Country, Through 2029
• Table 18 : Asia-Pacific Market for Humanized Monoclonal Antibodies, by Country, Through 2029
• Table 19 : Global Market for Chimeric Monoclonal Antibodies, by Region, Through 2029
• Table 20 : North American Market for Chimeric Monoclonal Antibodies, by Country, Through 2029
• Table 21 : European Market for Chimeric Monoclonal Antibodies, by Country, Through 2029
• Table 22 : Asia-Pacific Market for Chimeric Monoclonal Antibodies, by Country, Through 2029
• Table 23 : Global Market for Murine Monoclonal Antibodies, by Region, Through 2029
• Table 24 : North American Market for Murine Monoclonal Antibodies, by Country, Through 2029
• Table 25 : European Market for Murine Monoclonal Antibodies, by Country, Through 2029
• Table 26 : Asia-Pacific Market for Murine Monoclonal Antibodies, by Country, Through 2029
• Table 27 : Global Market for Antibody Drugs, by Manufacturing Process, Through 2029
• Table 28 : Global Market for Antibody Drugs Produced by Mammalian Cell Culture, by Region, Through 2029
• Table 29 : North American Market for Antibody Drugs Produced by Mammalian Cell Culture, by Country, Through 2029
• Table 30 : European Market for Antibody Drugs Produced by Mammalian Cell Culture, by Country, Through 2029
• Table 31 : Asia-Pacific Market for Antibody Drugs Produced by Mammalian Cell Culture, by Country, Through 2029
• Table 32 : Global Market for Antibody Drugs Produced by Microbial Cell Fermentation, by Region, Through 2029
• Table 33 : North American Market for Antibody Drugs Produced by Microbial Cell Fermentation, by Country, Through 2029
• Table 34 : European Market for Antibody Drugs Produced by Microbial Cell Fermentation, by Country, Through 2029
• Table 35 : Asia-Pacific Market for Antibody Drugs Produced by Microbial Cell Fermentation, by Country, Through 2029
• Table 36 : Global Market for Antibody Drugs, by Application, Through 2029
• Table 37 : Types of Autoimmune Diseases
• Table 38 : Global Antibody Drugs Market for Autoimmune Diseases, by Region, Through 2029
• Table 39 : North American Market for Antibody Drugs for Autoimmune Diseases, by Country, Through 2029
• Table 40 : European Market for Antibody Drugs for Autoimmune Diseases, by Country, Through 2029
• Table 41 : Asia-Pacific Market for Antibody Drugs for Autoimmune Diseases, by Country, Through 2029
• Table 42 : Global Market for Antibody Drugs for Solid Tumors, by Region, Through 2029
• Table 43 : North American Market for Antibody Drugs for Solid Tumors,, by Country, Through 2029
• Table 44 : European Market for Antibody Drugs for Solid Tumors, by Country, Through 2029
• Table 45 : Asia-Pacific Market for Antibody Drugs for Solid Tumors, by Country, Through 2029
• Table 46 : Types of Leukemia
• Table 47 : Global Market for Antibody Drugs for Lymphoma, Leukemia and Multiple Myeloma, by Region, Through 2029
• Table 48 : North American Market for Antibody Drugs for Lymphoma, Leukemia and Multiple Myeloma, by Country, Through 2029
• Table 49 : European Market for Antibody Drugs for Lymphoma, Leukemia and Multiple Myeloma, by Country, Through 2029
• Table 50 : Asia-Pacific Market for Antibody Drugs for Lymphoma, Leukemia and Multiple Myeloma, by Country, Through 2029
• Table 51 : Global Market for Antibody Drugs for Other Diseases, by Region, Through 2029
• Table 52 : North American Market for Antibody Drugs for Other Diseases, by Country, Through 2029
• Table 53 : European Market for Antibody Drugs for Other Diseases, by Country, Through 2029
• Table 54 : Asia-Pacific Market for Antibody Drugs for Other Diseases, by Country, Through 2029
• Table 55 : Global Market for Antibody Drugs, by Region, Through 2029
• Table 56 : North American Market for Antibody Drugs, by Country, Through 2029
• Table 57 : North American Market for Antibody Drugs, by Antibody Type, Through 2029
• Table 58 : North American Market for Antibody Drugs, by Manufacturing Process, Through 2029
• Table 59 : North American Market for Antibody Drugs, by Application, Through 2029
• Table 60 : European Market for Antibody Drugs, by Country, Through 2029
• Table 61 : European Market for Antibody Drugs, by Antibody Type, Through 2029
• Table 62 : European Market for Antibody Drugs, by Manufacturing Process, Through 2029
• Table 63 : European Market for Antibody Drugs, by Application, Through 2029
• Table 64 : Asia-Pacific Market for Antibody Drugs, by Country, Through 2029
• Table 65 : Asia-Pacific Market for Antibody Drugs, by Antibody Type, Through 2029
• Table 66 : Asia-Pacific Market for Antibody Drugs, by Manufacturing Process, Through 2029
• Table 67 : Asia-Pacific Market for Antibody Drugs, by Application, Through 2029
• Table 68 : RoW Market for Antibody Drugs, by Antibody Type, Through 2029
• Table 69 : RoW Market for Antibody Drugs, by Manufacturing Process, Through 2029
• Table 70 : RoW Market for Antibody Drugs, by Application, Through 2029
• Table 71 : Top Antibody Drug Companies, by Sales, 2023
• Table 72 : Major Acquisitions and Alliances in the Antibody Drugs Industry, 2022-2024
• Table 73 : Monoclonal Antibodies in Phase I Clinical TrialsMonoclonal Antibodies in Phase I Clinical Trials
• Table 74 : Monoclonal Antibodies in Phase II Clinical Trials
• Table 75 : Monoclonal Antibodies in Phase III Clinical Trials
• Table 76 : Monoclonal Antibodies in Phase IV Clinical Trials
• Table 77 : ESG Rankings for Major Antibody Drug Companies, 2024*
• Table 78 : ESG: Environmental Overview
• Table 79 : ESG: Social Factors Overview
• Table 80 : ESG: Governance Overview
• Table 81 : Report Sources
• Table 82 : Glossary of Terms Used in the Antibody Drugs Market
• Table 83 : AbbVie Inc.: Company Snapshot
• Table 84 : AbbVie Inc.: Financial Performance, FY 2022 and 2023
• Table 85 : AbbVie Inc.: Product Portfolio
• Table 86 : AbbVie Inc.: News/Key Developments, 2022-2024
• Table 87 : Amgen Inc.: Company Snapshot
• Table 88 : Amgen Inc.: Financial Performance, FY 2022 and 2023
• Table 89 : Amgen Inc.: Product Portfolio
• Table 90 : Amgen Inc.: News/Key Developments, 2022-2023
• Table 91 : AstraZeneca: Company Snapshot
• Table 92 : AstraZeneca: Financial Performance, FY 2022 and 2023
• Table 93 : AstraZeneca: Product Portfolio
• Table 94 : AstraZeneca: News/Recent Developments, 2021-2024
• Table 95 : Bristol-Myers Squibb Co.: Company Snapshot
• Table 96 : Bristol-Myers Squibb Co.: Financial Performance, FY 2022 and 2023
• Table 97 : Bristol-Myers Squibb Co.: Product Portfolio
• Table 98 : Bristol-Myers Squibb Co.: News/Key Developments, 2022-2023
• Table 99 : F. Hoffmann-La Roche Ltd.: Company Snapshot
• Table 100 : F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2022 and 2023
• Table 101 : F. Hoffmann-La Roche Ltd.: Product Portfolio
• Table 102 : F. Hoffmann-La Roche Ltd.: News/Key Developments, 2023-2024
• Table 103 : Johnson & Johnson Services Inc.: Company Snapshot
• Table 104 : Johnson & Johnson Services Inc.: Financial Performance, FY 2022 and 2023
• Table 105 : Johnson & Johnson Services Inc.: Product Portfolio
• Table 106 : Johnson & Johnson Services Inc.: News/Key Developments, 2022-2024
• Table 107 : Lilly: Company Snapshot
• Table 108 : Lilly: Financial Performance, FY 2022 and 2023
• Table 109 : Lilly: Product Portfolio
• Table 110 : Lilly: News/Key Developments, 2023-2024
• Table 111 : Merck KGaA: Company Snapshot
• Table 112 : Merck KGaA: Financial Performance, FY 2022 and 2023
• Table 113 : Merck KGaA: Product Portfolio
• Table 114 : Merck KGaA: News/Key Developments, 2022-2024
• Table 115 : Novartis AG: Company Snapshot
• Table 116 : Novartis AG: Financial Performance, FY 2022 and 2023
• Table 117 : Novartis AG: Product Portfolio
• Table 118 : Novartis AG: News/Key Developments, 2022-2024
• Table 119 : Pfizer Inc.: Company Snapshot
• Table 120 : Pfizer Inc.: Financial Performance, FY 2022 and 2023
• Table 121 : Pfizer Inc.: Product Portfolio
• Table 122 : Pfizer Inc.: News/Key Developments, 2023
• Table 123 : Regeneron Pharmaceuticals Inc.: Company Snapshot
• Table 124 : Regeneron Pharmaceuticals Inc.: Financial Performance, FY 2022 and 2023
• Table 125 : Regeneron Pharmaceuticals Inc.: Product Portfolio
• Table 126 : Regeneron Pharmaceuticals Inc.: News/Key Developments, 2022-2023
• Table 127 : Sanofi: Company Snapshot
• Table 128 : Sanofi: Financial Performance, FY 2022 and 2023
• Table 129 : Sanofi: Product Portfolio
• Table 130 : Sanofi: News/Key Developments, 2022-2023

List of Figures

• Summary Figure : Global Market Share of Antibody Drugs, by Region, 2023
• Figure 1 : Dynamics of the Global Market for Antibody Drugs
• Figure 2 : Emerging Technologies in the Antibody Drugs Market
• Figure 3 : Global Market Share of Antibody Drugs, by Antibody Type, 2023
• Figure 4 : Global Market for Human Monoclonal Antibodies, by Region, 2021-2029
• Figure 5 : Global Market for Humanized Monoclonal Antibodies, by Region, 2021-2029
• Figure 6 : Global Market for Chimeric Monoclonal Antibodies, by Region, 2021-2029
• Figure 7 : Global Market for Murine Monoclonal Antibodies, by Region, 2021-2029
• Figure 8 : Global Market Share of Antibody Drugs, by Manufacturing Process, 2023
• Figure 9 : Global Market for Antibody Drugs Produced by Mammalian Cell Culture, by Region, 2021-2029
• Figure 10 : Global Market for Antibody Drugs Produced by Microbial Cell Fermentation, by Region, 2021-2029
• Figure 11 : Global Market Share of Antibody Drugs, by Application, 2023
• Figure 12 : Global Antibody Drugs Market for Autoimmune Diseases, by Region, 2021-2029
• Figure 13 : Global Market for Antibody Drugs for Solid Tumors, by Region, 2021-2029
• Figure 14 : Global Market for Antibody Drugs for Lymphoma, Leukemia and Multiple Myeloma, by Region, 2021-2029
• Figure 15 : Global Market for Antibody Drugs for Other Diseases, by Region, 2021-2029
• Figure 16 : Global Market Share of Antibody Drugs, by Region, 2023
• Figure 17 : Global Market for Antibody Drugs, by Region, 2021-2029
• Figure 18 : North American Market Share of Antibody Drugs, by Country, 2023
• Figure 19 : U.S. Market for Antibody Drugs, 2021-2029
• Figure 20 : Canadian Market for Antibody Drugs, 2021-2029
• Figure 21 : Mexican Market for Antibody Drugs, 2021-2029
• Figure 22 : European Market Share of Antibody Drugs, by Country, 2023
• Figure 23 : German Market for Antibody Drugs, 2021-2029
• Figure 24 : French Market for Antibody Drugs, 2021-2029
• Figure 25 : Italian Market for Antibody Drugs, 2021-2029
• Figure 26 : Spanish Market for Antibody Drugs, 2021-2029
• Figure 27 : U.K. Market for Antibody Drugs, 2021-2029
• Figure 28 : Rest of Europe Market for Antibody Drugs, 2021-2029
• Figure 29 : Asia-Pacific Market Share of Antibody Drugs, by Country, 2023
• Figure 30 : Chinese Market for Antibody Drugs, 2021-2029
• Figure 31 : Japanese Market for Antibody Drugs, 2021-2029
• Figure 32 : Indian Market for Antibody Drugs, 2021-2029
• Figure 33 : Australian Market for Antibody Drugs, 2021-2029
• Figure 34 : South Korean Market for Antibody Drugs, 2021-2029
• Figure 35 : Rest of Asia-Pacific Market for Antibody Drugs, 2021-2029
• Figure 36 : Global Market Share of Human Monoclonal Antibodies, by Key Manufacturers/Suppliers, 2023
• Figure 37 : Global Market Share of Humanized Monoclonal Antibodies, by Key Manufacturers/Suppliers, 2023
• Figure 38 : Global Market Share of Chimeric Monoclonal Antibodies, by Key Manufacturers/Suppliers, 2023
• Figure 39 : Key ESG Metrics of Antibody Drugs Companies
• Figure 40 : AbbVie Inc.: Revenue Shares, by Business Unit, FY 2023
• Figure 41 : AbbVie Inc.: Revenue Shares, by Country/Region, FY 2023
• Figure 42 : Amgen Inc.: Revenue Shares, by Product, FY 2023
• Figure 43 : Amgen Inc.: Revenue Shares, by Country/Region, FY 2023
• Figure 44 : AstraZeneca: Revenue Shares, by Therapy Areas, FY 2023
• Figure 45 : AstraZeneca: Revenue Shares, by Region/Country, FY 2023
• Figure 46 : Bristol-Myers Squibb Co.: Revenue Shares, by Business Unit, FY 2023
• Figure 47 : Bristol-Myers Squibb Co.: Revenue Shares, by Country/Region, FY 2023
• Figure 48 : F. Hoffmann-La Roche Ltd.: Revenue Shares, by Business Unit, FY 2023
• Figure 49 : F. Hoffmann-La Roche Ltd.: Revenue Shares, by Country/Region, FY 2023
• Figure 50 : Johnson & Johnson Services Inc.: Revenue Shares, by Business Unit, FY 2023
• Figure 51 : Johnson & Johnson Services Inc.: Revenue Shares, by Country/Region, FY 2023
• Figure 52 : Lilly: Revenue Shares, by Business Unit, FY 2023
• Figure 53 : Lilly: Revenue Shares, by Country/Region, FY 2023
• Figure 54 : Merck KGaA: Revenue Shares, by Business Unit, FY 2023
• Figure 55 : Merck KGaA: Revenue Shares, by Country/Region, FY 2023
• Figure 56 : Novartis AG: Revenue Shares, by Business Unit, FY 2023
• Figure 57 : Novartis AG: Revenue Shares, by Country/Region, FY 2023
• Figure 58 : Pfizer Inc.: Revenue Shares, by Business Unit, FY 2023
• Figure 59 : Pfizer Inc.: Revenue Shares, by Country/Region, FY 2023
• Figure 60 : Regeneron Pharmaceuticals Inc.: Revenue Shares, by Product Sales, FY 2023
• Figure 61 : Regeneron Pharmaceuticals Inc.: Revenue Shares, by Country/Region, FY 2023
• Figure 62 : Sanofi: Revenue Shares, by Business Unit, FY 2023
• Figure 63 : Sanofi: Revenue Shares, by Country/ Region, FY 2023